drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and induction of apoptosis.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Other treatment
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre‑B and mature B lymphocytes, triggering complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and direct apoptosis to deplete CD20-positive B cells.
drug_name
Rituximab
nct_id_drug_ref
NCT06090539